The ENGOT-ov65/KEYNOTE-B96 trial reported small but clinically relevant progression-free survival increments and significantly improved overall survival in platinum-resistant ovarian cancer

Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer 

The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis

A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed

Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours

Patients with homologous-recombination-deficient advanced ovarian cancer alive at 5 years were twice as likely to be progression free with niraparib than placebo, although no long-term overall survival benefit was reported 

The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination

New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression

While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design